

Day 2 May 24 (Thu.)

Scientific Program Educational Session Oral Session Social Event Plenary Session English Session

| | | 7:00 | 8:00 | 9:00 | 10:00 | 11:00 | 12:00 | 13:00 | 14:00 | 15:00 | 16:00 | 17:00 | 18:00 | 19:00 | 20:00 | 21:00 |
|------------------------------------|----------------|--------------------------|---|------------------------------|--|--|-------------------------------|-------|-----------------------------------|---|--|---|---|----------------------------|-------|----------------------------------|
| Sapporo Gelbukkan | Room1 | Nitori Culture Hall (1F) | Hot Topics 01 Large scale multicenter studies of dementia | | | | | | Pr-01 President Lecture | Members Meeting Award Ceremony | AW-01 2017 Japanese Society of Neurology Award Winner Lecture | Symposium 13 Recent progress in clinical aspects of dementia | | | | |
| | Room2 | Zuiseitsu (3F) | Hot Topics 03 Prediction of Parkinson's disease dementia | | O-13 Parkinsonism and Related disorders (Imaging 1) | LS-10 Sumitomo Dainippon Pharma Co.,Ltd. | | | SPL-01 Semi-Plenary Lecture 01 | | Neuroscience Frontier Symposium 02 Intra- & into-the- brain propagation of α-synuclein; significance for the pathogenesis, progression and therapeutic target of Lewy body diseases | | PES-01 Premium Evening Seminar 01 Sapporo Prince Hotel International Convention Center PAMIR 3F [Onuma] | | | |
| | Room3 | Hourai (3F) | Symposium 06 The direction of clinical, educational, research in the future medicine from the key persons of the administration. | | O-14 Dementia (semiology) | LS-11 Bayer Yakuhin, Ltd. | | | | Symposium 14 Current status of secondary prevention of ischemic stroke | | | | | | |
| | Room4 | Reimei (3F) | Symposium 07 Basic and translational research of cerebral ischemia | | O-15 Cerebrovascular disease (Prognostic factor) | LS-12 GE Healthcare Japan Corporation/ Nihon Medi-Physics Co., Ltd. | | | | Overcome the Challenges of Neurological Disorders 03 Perspectives of next generation registry-cohort study -for target molecule and drug discovery | | ES-01 Medtronic Japan Co., Ltd | | | | |
| | Room5 | Seiryu (3F) | Symposium 08 what's new in myoclonus | | O-16 Parkinsonism and Related disorders (semiology) | LS-13 FP Pharmaceutical Corporation | | | | | | | | ES-02 Pfizer Japan Inc. | | |
| | Room6 | Gyokuyou (3F) | | | | O-17 Neuroimmunology (MS and NMO1) | LS-14 Astellas Pharma Inc. | | | | Symposium 15 Development of new diagnostic and therapeutic methods in human prion diseases | | | | | |
| Royton Sapporo | Room7 | Castle (1F) | Symposium 09 Medical Care Provision System based on the Intractable Disease Health Care Act ~Mission of Neurologists~ | | O-18 Medical care and others | LS-15 Novartis Pharma K.K | | | | Symposium 16 Frontier of study for GBS and CIDP. -from molecular basis to cohort study- | | | | | | |
| | Room8 | Empress Hall (2F) | Symposium 10 New approach to the cerebral small vessel disease | | O-19 Cerebrovascular disease (Clinical research 1) | LS-16 Mitsubishi Tanabe Pharma Corporation | | | | Symposium 17 To pursue the best treatment of MG | | | | | | H-1 Resident Clinical Tournament |
| | Room9 | Regent Hall (2F) | Symposium 11 Current topics in acute encephalitis update - advance in diagnosis and treatment of autoimmune encephalitis | | O-20 Neuroinfection (CJD and encephalitis) | LS-17 DAIICHI SANKYO CO.,LTD. | | | | Hot Topics 04 Toward the early diagnosis and treatment of Progressive Supranuclear Palsy | | ES-03 Takeda Pharmaceutical Company Limited | | | | |
| | Room10 | Highness Hall (2F) | LM-03 Lecture Marathon 03 | LM-04 Lecture Marathon 04 | O-21 Peripheral neuropathy/ Metabolic disorders | LS-18 GlaxoSmithKline.KK | | | | LM-05 Lecture Marathon 05 | LM-06 Lecture Marathon 06 | ES-04 Janssen Pharmaceutical K.K. | | | | |
| | Room11 | Crystal Room A (2F) | | | O-22 Neuromuscular junction disorders and myopathy | LS-19 NIHON PHARMACEUTICAL CO., LTD | | | | International Education Course 02 Movement disorders in general neurology | | | | | | |
| | Room12 | Crystal Room B (2F) | | | O-23 Neuropathology (Neurodegeneration) | LS-20 Sanofi K.K. | | | | | | | | | | |
| | Room13 | Crystal Room C (2F) | | | O-24 Neuroimmunology (Biomarker) | LS-21 InSightec Japan | | | | | | | | | | |
| | Room14 | Pearl Hall AB (20F) | Symposium 12 Current essentials of treatment for neurological metabolic disorders | | O-25 Neuroimmunology (Autoimmune encephalitis) | | | | | | | | | | | |
| Sapporo Education and Culture Hall | Room15 | Main Hall (1F) | | | | | LS-22 Biogen Japan Ltd. | | | | | | | | | |
| | Room16 | Small Hall (1F) | | | | | | | | | | | | | | |
| | Room17 | 301 (3F) | | | | | | | | | | | | | | |
| Royton | Poster Session | Royton Hall (3F) | Poster Preparation | | | | Poster Round | | | | Poster Session | | Poster Removal | | | |

DAY 2